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 Gout is the most prevalent inﬂammatory arthritis and affects 
2.5% of the general population in the UK. It is also the 
only arthritis that has the potential to be cured with safe, 
inexpensive and well tolerated urate-lowering treatments, 
which reduce serum uric acid by either inhibiting xanthine 
oxidase – eg allopurinol, febuxostat – or by increasing the 
renal excretion of uric acid. Of these, xanthine oxidase 
inhibitors are used ﬁrst line and are effective in ‘curing’ gout 
in the vast majority of patients. Gout can be diagnosed on 
clinical grounds in those with typical podagra. However, in 
those with involvement of other joints, joint aspiration is 
recommended to demonstrate monosodium urate crystals and 
exclude other causes of acute arthritis, such as septic arthritis. 
However, a clinical diagnosis of gout can be made if joint 
aspiration is not feasible. This review summarises the current 
understanding of the pathophysiology, clinical presentation, 
investigations and treatment of gout. 
 Introduction 
 Gout is the commonest inflammatory arthritis with a prevalence 
of 2.5% in the UK. 1 Although it has the potential to be cured, 
its treatment remains suboptimal, with 30–40% of eligible 
patients receiving urate-lowering treatment (ULT) generally 
at suboptimal doses and with adherence <40% at 12 months. 1 
This review summarises the current understanding of aetio-
pathogenesis, clinical features and management of gout. 
 Pathogenesis 
 Hyperuricaemia and monosodium urate crystal 
deposition 
 Gout results from sustained hyperuricaemia (serum uric acid 
(SUA) ≥360 µmol/L), which leads to intra- and/or peri-articular 
monosodium urate (MSU) crystal deposition. Uric acid (UA) is 
the end product of the breakdown of dietary and endogenous 
purines. SUA ranges 120–180 µmol/L in most animals because 
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they possess uricase, which breaks down UA to soluble 
allantoin. 2 SUA is higher in primates (eg humans, great apes) 
because of missense mutations in the uricase gene, occurring 
10–20 million years ago, and may have resulted in a survival 
advantage from its anti-hypotensive and anti-oxidant effects. 2 
 Hyperuricaemia arises from over-production (from increased 
breakdown of exogenous or endogenous purines) or renal 
under-excretion of UA. Renal under-excretion accounts for 
70% of urate load. 3 Recently, several transporters have been 
identified in the proximal renal tubules, collecting ducts 
and also in the gastrointestinal tract; this has advanced the 
understanding of the pathogenesis of hyperuricaemia (Fig  1 ). 
Key points
Gout is associated with metabolic syndrome and patients 
should be screened for obesity, diabetes mellitus, 
hypertension, hyperlipidaemia and cardiovascular diseases
A deﬁnite diagnosis of gout requires joint aspiration and 
polarised light microscopy of aspirated ﬂuid
Serum uric acid may be normal during an acute attack of gout
Acute gout can be managed by rest, ice packs and oral 
NSAIDs, low-dose colchicine or corticosteroids. If feasible, 
especially in a hospital setting, aspiration and injection of 
corticosteroid is recommended as the fastest acting option for 
acute gout
Indications for urate-lowering treatment (ULT) are more than 
one acute attack of gout in 12 months (in uncomplicated 
gout), or less frequent attacks in the presence of tophi, renal 
impairment, uric acid nephrolithiasis or a need to continue on 
diuretics for heart failure. However, ULT should be discussed and 
considered with patients even around the time of ﬁrst diagnosis
ULT dose should be up-titrated gradually aiming for a serum 
uric acid (SUA) ≤300 μmol/L. Once the SUA is below this level, 
it should be checked annually
KEYWORDS: colchicine, gout, hyperuricaemia, tophi, urate-
lowering treatment ■
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 Hyperuricaemia is central to the development of gout. 
It reduces urate solubility and promotes MSU crystal 
nucleation and growth. 4 The risk of gout increases 
exponentially with increasing SUA; nevertheless, only a 
minority of people with hyperuricaemia develop gout. For 
example, in the normative aging study, the 1-year incidence 
of gout in men was <0.1%, 0.4%, 0.8%, 4.3% and 7.0% 
for SUA <416 µmol/L, 416–475 µmol/L, 476–534 µmol/L, 
535–594 µmol/L, ≥595 µmol/L, respectively. 5 
 MSU crystal-induced inﬂ ammation 
 Once MSU crystals are released, they are phagocytosed 
by resident macrophages and other mononuclear cells 
and induce inflammation by activating the NALP-3 
inflammasome, which results in cleavage of pro-IL-1β and 
secretion of IL-1β. 6,7 NALP-3 inflammasome activation 
is central to MSU crystal-induced inflammation, as 
macrophages deficient in the NALP-3 inflammasome do 
not mount an inflammatory response to MSU crystals. 6 
Once activated, monocytes and macrophages release 
chemokines (eg CXCL-1, IL-8, C-GSF) that promote 
neutrophil chemotaxis, survival and proliferation. 6 
Other chemokines, such as CCL-2, recruit additional 
macrophages and monocytes, 6 resulting in secretion 
of TNF-α (promoting cellular activation, endothelial 
adhesion and phagocytosis) and further IL-1β (promoting 
endothelial adhesion, endogenous pyrogen) causing a 
self-propagating intense inflammatory response in which 
neutrophils release lysozymes on phagocytosing MSU 
crystals. Components of the innate immune system, eg toll-
like receptors and complement pathways, are also activated 
by MSU crystals. 6 
 Epidemiology 
 The prevalence of gout has increased dramatically in the UK. 1 
It is more common in men and increases with age, being 
uncommon in men younger than 40 years. 1 It is also rare 
in premenopausal women because of the uricosuric effect 
of oestrogen, progesterone and lower insulin resistance; 
consequently, the gender difference seen in prevalence reduces 
after the age of 60 years. 1,8 
 Other risk factors for gout include ethnicity (eg Afro-
Caribbean, South Pacific islanders); obesity; excess 
consumption of beer or spirits, red meat, seafood, 
fructose-sweetened beverages and fruit juices; medications 
(particularly diuretics); and hypertension, renal impairment 
and insulin resistance. 8 There is evidence that moderate 
consumption of purine-rich vegetables, fresh fruits, soya 
and wine do not increase the risk of gout. 8 The increased 
risk from excessive consumption of beer and spirits 
relates to their high purine content. 8 Other factors such as 
excessive breakdown of ATP and lactic acidosis after alcohol 
consumption – which generate a UA load and reduce UA 
excretion, respectively – also contribute. 8 Fructose is the 
only carbohydrate that increases UA levels by increasing ATP 
degradation and insulin resistance, which further reduces 
renal urate excretion. 8  Several dietary items reduce the risk 
of gout. For example, regular daily consumption of skimmed 
milk or at least alternate day consumption of yogurt, coffee 
(including decaffeinated coffee ≥4 cups/day) and vitamin 
C (0.5 gm/day) reduces SUA and risk of gout. 8 Cherry 
consumption reduces the risk of recurrent gout attacks and 
also lowers SUA modestly. 8 
 Clinical features 
 Acute gout 
 Acute gout attacks are characterised by typical features of 
acute crystal synovitis, such as rapid onset (symptoms peaking 
within 12–24 hours of onset), excruciating joint pain, exquisite 
tenderness to touch, erythema and articular/periarticular 
swelling. 9,10 The attack usually resolves in 1–2 weeks. The sites 
commonly affected include the first metatarsophalangeal 
joint (most frequently affected), knees, ankles, midfoot and, 
less commonly, wrists, elbows and bursae (eg the olecranon 
and pre-patellar bursae). Lower limb and mono-articular 
involvement are common early in the course of the disease, and 
oligo- and polyarticular presentations occur infrequently. Acute 
attacks can be precipitated by infection, injury, dehydration, 
excess alcohol or purine intake, and initiation of ULT. 11 Slowly 
uptitrated ULT, as recommended by several international 
guidelines, carries a lower risk of triggering acute attacks of 
gout than starting at a moderate to high dose of ULT. 12–15 
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 Fig 1.  Urate transport in the kidney. A – mechanism of reabsorption of uric acid; B – mechanism of uric acid secretion. Differences in the activity of these 
urate transporters result in hyperuricaemia. 
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 Chronic tophaceous gout 
 Chronic tophaceous gout usually develops after many years of 
recurrent acute attacks; however, it can occasionally develop 
more quickly, over a few years, with relatively few attacks. Gouty 
tophi are nodular masses of MSU crystals and inflammatory 
tissues, and appear as white to yellow firm subcutaneous 
deposits with often a heterogenous consistency, generally on the 
finger tips, feet and in the olecranon and pre-patellar bursae. 
Tophaceous gout presents with chronic joint pain, stiffness and 
tenderness, with superimposed episodes of acute gout. 
 Transplant-associated gout 
 Immunosuppressed solid organ transplant recipients on low-dose 
prednisolone and calcineurin inhibitors, such as ciclosporine, can 
present with rapidly progressive tophaceous gout. Unlike patients 
with primary gout, where tophi typically take over 10 years to 
develop, transplant recipients can develop tophi within 3–5 years. 15 
 Comorbidities 
 Obesity, insulin resistance, hypertension, hyperlipidaemia, renal 
impairment, ischaemic heart disease and congestive cardiac 
failure are common in people with gout and their presence 
should be sought specifically and treated appropriately. 15 
 Investigations 
 While the definite diagnosis of gout requires joint aspiration 
and polarised light microscopy of the synovial fluid, a 
confident clinical diagnosis of gout can be made in those with 
typical features of crystal-induced inflammation affecting the 
first metatarsophalangeal joint ( ‘podagra’ ) without recourse 
to joint aspiration. 15 Septic arthritis is the main differential 
diagnosis, but others include acute calcium pyrophosphate 
crystal arthritis (formerly ‘pseudogout’) and reactive arthritis. 
Gouty tophi can sometimes be confused with rheumatoid 
nodules although these are usually homogenous, not white in 
colour and occur in patients with rheumatoid factor or anti-
cyclic citrullinated peptide antibodies. 
 Peripheral blood 
 Neutrophilia and raised inflammatory markers are common 
in acute gout. SUA is a negative acute phase reactant and is 
often reduced during the acute attack, so should be rechecked 
1–2 weeks after resolution. Hyperuricaemia itself should not 
be used to diagnose gout as hyperuricaemia is common in the 
general population. SUA is greater than 360 µmol/L in 50.4% 
of men and 16.3% of women. 16 Renal function, liver function, 
glucose, lipid profile and full blood count should be checked to 
screen for chronic kidney disease (CKD), liver disease, diabetes, 
dyslipidaemia and myeloproliferative disorders. 
 Synovial ﬂ uid 
 Aspiration of the affected joint and prompt examination of 
the aspirated synovial fluid, which is often turbid with low 
viscosity, under plain and polarised light microscopy can 
readily confirm negatively-birefringent needle-shaped MSU 
crystals (Fig  2 ). Gram stain and culture of aspirated synovial 
fluid should also be performed to exclude septic arthritis, which 
can rarely coexist with gout. Synovial fluid leukocyte counts 
are not routinely performed but may be >10,000/mm 3 . MSU 
crystals can also be demonstrated in synovial fluid aspirated 
between attacks (the intercritical period). 
 Urinary uric acid excretion 
 Urinary uric acid excretion is rarely performed in clinical 
practice as xanthine oxidase inhibitors (XOIs) are extremely 
effective in treating gout, and need only be checked in those 
with premature onset gout, that is disease onset prior to 25 years 
of age, or if there is a family history of early-onset gout. 12–14 If 
required, a 24-hour urine collection is preferred over a spot uric 
acid creatinine ratio. 
 Radiography 
 Plain radiographic changes of gout (Box  1 , Fig  3 ) take several 
years to develop and are helpful in making a diagnosis in the 
later stages of gout. In contrast, ultrasonography is sensitive in 
detecting MSU crystal deposits. The ultrasonographic findings 
of gout include double contour sign (MSU crystal deposition on 
surface of hyaline articular cartilage), intra-articular and intra-
bursal tophi, and hyper-echoic aggregates (Fig  4 ). However, these 
findings are not 100% specific and may be present in joints with 
calcium pyrophosphate deposition. 17 Dual energy computerised 
tomography, which can demonstrate MSU crystals, is not widely 
available and has a limited role in early disease. 
 Treatment 
 Full patient education about gout and its treatment options, 
and involvement of the patient in management decisions are the 
cornerstones of successful treatment. 
 Fig 2.  Polarised light microscopy showing needle shaped negatively 
birefringent (change in colour of the MSU crystal on employing the 
polariser) monosodium urate crystal. Figure courtesy of the Department 
of Microbiology, Addenbrookes Hospital, Cambridge, UK.  
 Box 1.  Plain radiographic features of gout 
> Soft-tissue swelling during acute or tophaceous gout
>  Increased soft tissue density/calcification in tophaceous 
gout – eccentric
> Preserved joint space until late disease
>  Cortical erosions – well defined, marginal/intra-articular/away 
from joint line, with sclerotic margins and overhanging edge
> Absence of bony proliferation
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(eGFR)<30 mL/min) and avoided in the presence of interacting 
drugs – such as macrolides and statins. Statins should be 
temporarily omitted while the patient is taking colchicine because 
of increased risk of colchicine toxicity. 
 Monoarticular gout can be very effectively treated with 
joint aspiration and intra-articular corticosteroid injection, 
eg methylprednisolone or triamcinolone. Oral prednisolone 
at a dose of 20–35 mg/day should be used when NSAIDs and 
colchicine are contraindicated or poorly tolerated, or for 
oligo/polyarticular gout. Anti-IL-1 agents, such as anakinra, 
canakinumab and rilonacept, are effective treatments for acute 
gout but are not approved by the National Institute for Health 
and Care Excellence (NICE). 
 Long-term urate-lowering treatment 
 Long-term ULT should be explained and discussed with all 
gout patients at diagnosis. Current guidelines recommend 
ULT if a patient is getting regular acute attacks (>1 attack/year) 
or has tophi, renal impairment, transplant-associated gout, 
nephrolithiasis or needs to continue on diuretics for heart 
failure. 12–15 
 Although most patients with gout exhibit renal under-
excretion rather than overproduction of urate, the efficacy 
and tolerability of XOIs makes them the mainstay of ULT. 12–15 
British and European guidelines recommend that ULT should 
be started 1–2 weeks after the acute attack has subsided 
as reduction in SUA may prolong the current episode or 
precipitate another attack. However, the 2012 American 
guidelines support ULT initiation during an acute attack of 
gout. 12 Patients on ULT who develop an acute attack should 
continue on it. 12–15 ULT should be started at a low dose, and 
the dose gradually increased with monthly SUA measurement, 
aiming for a SUA <300 µmol/L. 15 
 Acute attack 
 Management includes rest, application of ice packs, and prompt 
use of non-steroidal anti-inflammatory drugs (NSAIDs), 
colchicine or corticosteroids. 12–15 These are most effective when 
started early, eg within the first 12–24 hours of onset. Any fast-
acting NSAID at full dose (eg naproxen, diclofenac) with a proton 
pump inhibitor may be prescribed. Although indomethacin is 
effective, it is best avoided because of frequent toxicity. Colchicine 
(0.5 mg two to three times per day) is also effective. These may be 
required for 1–2 weeks, and in order to prevent rebound attacks 
the treatment may be continued for 1–2 days after the acute 
attack has subsided. 12–14 Diarrhoea is the commonest side effect 
of colchicine. The dose of colchicine should be reduced in older 
patients, in those with CKD (estimated glomerular filtration rate 
 Fig 3.  Radiographs showing changes of gout. A – soft-tissue swelling around the index and little ﬁ nger proximal interphalangeal joints in a patient with 
tophaceous gout; B – erosion in the ﬁ rst metatarsophalangeal joint with overhanging edges; C – typical punched out erosions in the ﬁ rst metatarsophalangeal 
joint with sclerosis and preserved bone mineral density (c.f. in rheumatoid arthritis the bones appear osteopaenic). 
 Fig 4.  Ultrasound scan of the ﬁ rst metatarsophalangeal joint showing 
double contour sign (solid white arrow) and tophus (dashed white 
arrow) in the dorsal synovial recess. 
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 As patients starting ULT are at risk of recurrent gout attacks, 
co-prescription of colchicine (0.5 mg once to twice daily) for 
a period of 6 months should be considered. 15 If colchicine 
is not tolerated, NSAIDs or COX-2 inhibitors, or low dose 
prednisolone (eg 7.5 mg/day) may be used after discussion of 
risks and benefits. 15 
 Xanthine oxidase inhibitors 
 Allopurinol inhibits synthesis of UA by inhibiting xanthine 
oxidase. It is metabolised to oxypurinol, an active metabolite 
that is long acting and renally excreted. Allopurinol should 
be commenced at an initial dose of 100 mg/day (50 mg/day in 
presence of CKD stage ≥4), and the dose increased gradually (eg 
monthly) until a target SUA of <300 µmol/L or the maximum 
licensed dose is reached. The maximum dose of allopurinol 
should be reduced in the presence of renal impairment and 
specialist advice sought. The American College of Rheumatology 
recommends that the dose of allopurinol may be cautiously 
increased to over 300 mg/day in patients with renal impairment 
if it is commenced at a low dose (eg 50 mg/day) and the dose 
escalated gradually, with careful screening for adverse events. 12 
 Allopurinol may cause adverse events, including allopurinol 
hypersensitivity syndrome (mortality <25%, incidence 
<1:1000), which presents as an erythematous desquamating 
rash, fever, hepatitis, eosinophilia and worsening renal 
function. It is more common in Koreans and Han Chinese 
than in Caucasians, and in those with renal failure, especially 
if commenced on a high dose of the drug (eg 300 mg/day). 
The treatment of allopurinol hypersensitivity syndrome is 
supportive. Such patients may be commenced on febuxostat, 
a newer non-purine XOI, after careful discussion and close 
monitoring as febuxostat can itself associate with drug reaction 
with eosinophilia and systemic symptoms (DRESS syndrome). 
However, there are limited published data to conclude that there 
is no cross-reactivity between allopurinol and febuxostat. 18 
 Febuxostat is started at 80 mg/day in the UK with the dose 
increased to 120 mg/day, if required. It is not licensed for 
use in renal impairment (eGFR<30 mL/min) or in those 
with ischaemic heart disease. One recent study suggests that 
febuxostat may be safe in CKD stage 4; however, such use 
remains unlicensed and should only be used after careful 
discussion with the patient. 19  Allopurinol and febuxostat 
should not be co-prescribed with azathioprine as inhibition 
of azathioprine metabolism leads to severe blood dyscrasias. 
Use of febuxostat in people with ischaemic heart disease or 
congestive cardiac failure is not approved by NICE. 
 Uricosuric drugs 
 Uricosuric drugs have limited availability in the UK. Probenecid 
and sulfinpyrazone have lower potency than benzbromarone, 
are less effective in renal impairment (eGFR<30 mL/min) and 
sulfinpyrazone frequently causes gastrointestinal side effects. 
Benzbromarone is extremely potent and better tolerated, 
but is not licensed for use in the UK because of reports of 
fulminant liver failure in Japanese patients. 20 Probenecid and 
benzbromarone are sourced from Europe and should only be 
used after documenting informed consent. Benzbromarone is 
effective in patients with eGFR>20 mmol/L. 15 Uricosuric drugs 
can be combined with XOIs if required. 
 Fenofibrate and losartan have uricosuric effects and may be 
used as adjuncts to XOIs when otherwise indicated. Of these, 
fenofibrate 200–300 mg/day (micronized) reduces SUA by 
approximately 100 µmol/L, while losartan 50 mg/day reduces 
SUA by 47 µmol/L with no further reduction at higher doses. 21,22 
 Newer anti-gout treatments 
 Lesinurad, a new uricosuric drug, has been approved in the 
EU in combination with an XOI and is currently undergoing 
NICE appraisal. PEGylated uricase is effective in reducing 
tophus burden in patients with treatment failure to other ULTs; 
however, it is not NICE approved and is currently unavailable 
in the UK. 
 Dietary and lifestyle adjuncts 
 Dietary modifications to achieve ideal weight should be 
attempted, as this reduces insulin resistance and SUA levels. 
However, there are no randomised controlled trials and effects 
of dietary modifications on SUA are modest. For instance, 
vitamin C (≥500 mg/day) reduces SUA by c40 µmol/L with 
significant heterogeneity of effects. 23 
 Managing comorbidities 
 Losartan and amlodipine should be used preferentially to 
treat hypertension and diuretics and beta-blockers should 
be avoided as they cause hyperuricaemia and associate with 
gout. 24 Hyperlipidaemia should be treated with atorvastatin 
or fenofibrate. 24 The cardiovascular benefit from low-dose 
aspirin outweighs the insignificant risk of hyperuricaemia 
from reduced renal urate excretion, and it should be continued 
if indicated. 15 Similarly, diuretics prescribed for heart failure 
should be continued but bendroflumethiazide prescribed 
for hypertension should be changed to an alternative 
antihypertensive. ■ 
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